Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 2
1987 3
1988 3
1989 3
1990 4
1991 2
1992 2
1993 1
1995 2
1996 1
1997 5
1998 4
1999 2
2000 8
2001 5
2002 2
2003 5
2004 7
2005 7
2006 5
2007 7
2008 10
2009 7
2010 5
2011 8
2012 7
2013 10
2014 7
2015 13
2016 3
2017 4
2018 3
2019 4
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Results by year
Filters applied: . Clear all
Page 1
Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.
McClurg UL, Chit NCTH, Azizyan M, Edwards J, Nabbi A, Riabowol KT, Nakjang S, McCracken SR, Robson CN. McClurg UL, et al. Among authors: Robson CN. Oncogene. 2018 Aug;37(34):4679-4691. doi: 10.1038/s41388-018-0283-3. Epub 2018 May 14. Oncogene. 2018. PMID: 29755129
Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.
McClurg UL, Nabbi A, Ricordel C, Korolchuk S, McCracken S, Heer R, Wilson L, Butler LM, Irving-Hooper BK, Pedeux R, Robson CN, Riabowol KT, Binda O. McClurg UL, et al. Among authors: Robson CN. Br J Cancer. 2018 Mar 6;118(5):713-726. doi: 10.1038/bjc.2017.447. Epub 2018 Jan 30. Br J Cancer. 2018. PMID: 29381681 Free PMC article.
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.
Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. Munkley J, et al. Among authors: Robson CN. EBioMedicine. 2016 Jun;8:103-116. doi: 10.1016/j.ebiom.2016.04.018. Epub 2016 Apr 20. EBioMedicine. 2016. PMID: 27428423 Free PMC article.
The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.
McClurg UL, Azizyan M, Dransfield DT, Namdev N, Chit NCTH, Nakjang S, Robson CN. McClurg UL, et al. Among authors: Robson CN. Oncotarget. 2018 May 18;9(38):24992-25007. doi: 10.18632/oncotarget.25167. eCollection 2018 May 18. Oncotarget. 2018. PMID: 29861848 Free PMC article.
The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.
Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, Berry P, Cassidy JR, Moad M, El-Sherif A, Gaughan L, Mills IG, Robson CN, Heer R. Hepburn AC, et al. Among authors: Robson CN. Version 2. Oncogene. 2019 May;38(22):4412-4424. doi: 10.1038/s41388-019-0712-y. Epub 2019 Feb 11. Oncogene. 2019. PMID: 30742096 Free PMC article.
Deubiquitinating enzymes as oncotargets.
McClurg UL, Robson CN. McClurg UL, et al. Among authors: Robson CN. Oncotarget. 2015;6(12):9657-68. doi: 10.18632/oncotarget.3922. Oncotarget. 2015. PMID: 25962961 Free PMC article. Review.
Using induced pluripotent stem cells as a tool for modelling carcinogenesis.
Curry EL, Moad M, Robson CN, Heer R. Curry EL, et al. Among authors: Robson CN. World J Stem Cells. 2015 Mar 26;7(2):461-9. doi: 10.4252/wjsc.v7.i2.461. World J Stem Cells. 2015. PMID: 25815129 Free PMC article. Review.
Alternative splicing and biological heterogeneity in prostate cancer.
Rajan P, Elliott DJ, Robson CN, Leung HY. Rajan P, et al. Among authors: Robson CN. Nat Rev Urol. 2009 Aug;6(8):454-60. doi: 10.1038/nrurol.2009.125. Nat Rev Urol. 2009. PMID: 19657379 Review.
156 results
Jump to page
Feedback